Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma.
Publication
, Conference
Rizzieri, DA; Akabani, G; Zalutsky, M; Coleman, RE; Toaso, B; Anderson, E; Lagoo, A; Clayton, S; Niedzwiecki, D; Moore, JO; Gockerman, JP ...
Published in: BLOOD
November 16, 2003
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
635A / 636A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Rizzieri, D. A., Akabani, G., Zalutsky, M., Coleman, R. E., Toaso, B., Anderson, E., … Bigner, D. D. (2003). Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma. In BLOOD (Vol. 102, pp. 635A-636A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
Rizzieri, D. A., G. Akabani, M. Zalutsky, R. E. Coleman, B. Toaso, E. Anderson, A. Lagoo, et al. “Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma.” In BLOOD, 102:635A-636A. AMER SOC HEMATOLOGY, 2003.
Rizzieri DA, Akabani G, Zalutsky M, Coleman RE, Toaso B, Anderson E, et al. Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 635A-636A.
Rizzieri, D. A., et al. “Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma.” BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 635A-636A.
Rizzieri DA, Akabani G, Zalutsky M, Coleman RE, Toaso B, Anderson E, Lagoo A, Clayton S, Niedzwiecki D, Moore JO, Gockerman JP, DeCastro C, Chao NJ, Gasparetto C, Bigner DD. Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 635A-636A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2003
Volume
102
Issue
11
Start / End Page
635A / 636A
Location
SAN DIEGO, CALIFORNIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology